Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

BACKGROUND: Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations. Patterns of CLL evolution under ibrutinib therapy are well characterized...

Descripción completa

Detalles Bibliográficos
Autores principales: Cadot, Sarah, Valle, Carine, Tosolini, Marie, Pont, Frederic, Largeaud, Laetitia, Laurent, Camille, Fournie, Jean Jacques, Ysebaert, Loic, Quillet-Mary, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724843/
https://www.ncbi.nlm.nih.gov/pubmed/33298182
http://dx.doi.org/10.1186/s40364-020-00253-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724843/
https://www.ncbi.nlm.nih.gov/pubmed/33298182
http://dx.doi.org/10.1186/s40364-020-00253-w

Ejemplares similares